Allegro Ophthalmics

Allegro Ophthalmics is dedicated to delivering and establishing Integrin Peptide TherapyTM.

With over 100 years of combined experience, the seasoned leadership team at Allegro Ophthalmics is dedicated to establishing Integrin Peptide Therapy as the next generation pharmaceutical category for the treatment of vitreo-retinal diseases. Currently in Phase 2 studies for multiple indications, Allegro’s lead investigational drug Luminate has been shown to significantly reduce the current burden of intravitreal injections and to be a viable option for patients with wet age-related macular degeneration and diabetic macular edema. By quickly, safely and cost-effectively bringing to market new and improved treatment options for leading causes of blindness, Allegro is committed to offering patients an improved quality of life by self-sufficient, functional vision.